Journal Articles Gastroenterology Year : 2021

Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)

Abstract

VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes.
ClinicalTrials.gov NCT02497469; EudraCT 2015-000939-33.
Fichier principal
Vignette du fichier
S0016508521031267.pdf (1) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04214563 , version 1 (22-07-2024)

Licence

Identifiers

Cite

Laurent Peyrin-Biroulet, Edward Loftus, Jean-Frédéric Colombel, Silvio Danese, Raquel Rogers, et al.. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology, 2021, 161 (4), pp.1156-1167.e3. ⟨10.1053/j.gastro.2021.06.015⟩. ⟨hal-04214563⟩
37 View
31 Download

Altmetric

Share

More